UBS Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,270
| Closed | -$11K | – | 11326 |
|
|
2021
Q3 | $11K | Buy |
2,270
+685
| +43% | +$3.33K | ﹤0.01% | 7967 |
|
|
2021
Q2 | $9K | Sell |
1,585
-1,361
| -46% | -$7.04K | ﹤0.01% | 8202 |
|
|
2021
Q1 | $14K | Sell |
2,946
-736
| -20% | -$3.84K | ﹤0.01% | 7708 |
|
|
2020
Q4 | $16K | Buy |
3,682
+3,674
| +45,925% | +$15.7K | ﹤0.01% | 7141 |
|
|
2020
Q3 | $0 | Sell |
8
-857
| -99% | -$3.31K | ﹤0.01% | 8648 |
|
|
2020
Q2 | $2K | Sell |
865
-13,695
| -94% | -$40.2K | ﹤0.01% | 7703 |
|
|
2020
Q1 | $43K | Sell |
14,560
-16,899
| -54% | -$75.7K | ﹤0.01% | 5960 |
|
|
2019
Q4 | $119K | Buy |
31,459
+17,638
| +128% | +$84.4K | ﹤0.01% | 5915 |
|
|
2019
Q3 | $70K | Buy |
13,821
+12,956
| +1,498% | +$80K | ﹤0.01% | 5993 |
|
|
2019
Q2 | $5K | Sell |
865
-181
| -17% | -$1.04K | ﹤0.01% | 7411 |
|
|
2019
Q1 | $7K | Sell |
1,046
-3,148
| -75% | -$28.3K | ﹤0.01% | 7039 |
|
|
2018
Q4 | $35K | Buy |
4,194
+729
| +21% | +$9.48K | ﹤0.01% | 6372 |
|
|
2018
Q3 | $69K | Hold |
3,465
| – | – | ﹤0.01% | 5905 |
|
|
2018
Q2 | $90K | Sell |
3,465
-191,038
| -98% | -$5.29M | ﹤0.01% | 5520 |
|
|
2018
Q1 | $4.65M | Buy |
194,503
+155,559
| +399% | +$4.9M | ﹤0.01% | 2383 |
|
|
2017
Q4 | $1.32M | Buy |
38,944
+10,377
| +36% | +$290K | ﹤0.01% | 3538 |
|
|
2017
Q3 | $605K | Buy |
+28,567
| New | +$524K | ﹤0.01% | 4078 |
|
|
2017
Q1 | – | Sell |
-1,536
| Closed | -$26K | – | 8132 |
|
|
2016
Q4 | $26K | Sell |
1,536
-353
| -19% | -$5.46K | ﹤0.01% | 6350 |
|
|
2016
Q3 | $31K | Buy |
+1,889
| New | +$28.7K | ﹤0.01% | 5905 |
|
|
2016
Q1 | – | Sell |
-1,891
| Closed | -$54K | – | 8395 |
|
|
2015
Q4 | $54K | Buy |
1,891
+894
| +90% | +$15.1K | ﹤0.01% | 5750 |
|
|
2015
Q3 | $17K | Buy |
997
+598
| +150% | +$13.6K | ﹤0.01% | 6871 |
|
|
2015
Q2 | $10K | Sell |
399
-449
| -53% | -$8.73K | ﹤0.01% | 7490 |
|
|
2015
Q1 | $15K | Buy |
848
+258
| +44% | +$4.42K | ﹤0.01% | 7305 |
|
|
2014
Q4 | $10K | Buy |
+590
| New | +$8.95K | ﹤0.01% | 8421 |
|
UBS Group's ADMS Position: Q4 2021 in Review
UBS Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 2,270 shares — an estimated $11K sold.
UBS Group first reported a position in ADMS in Q4 2014 and held it in 24 quarters. The position peaked at $4.65M in Q1 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- UBS Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- UBS Group sold 2,270 Adamas Pharmaceuticals shares in Q4 2021, an estimated $11K.
- UBS Group first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 24 quarters.
- UBS Group's Adamas Pharmaceuticals position peaked at $4.65M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.